Smallpox

Infectious Disease MONDO:0004651 Pathograph 14 Show in embeddings browser Orthopoxvirus Infection Viral Exanthem

Smallpox is the eradicated systemic orthopoxvirus disease caused by Variola virus, a large double-stranded DNA virus restricted to humans. After respiratory-mucosal seeding, variola infected macrophages and regional lymph nodes, disseminated in a cell-associated viremia to lymphoreticular tissues, dermis, mucosa, liver, and other organs, and produced a synchronous centrifugal vesiculopustular exanthem whose ordinary, flat, and hemorrhagic clinical forms differed sharply in fatality.

Ask OpenScientist

Ask a research question about Smallpox. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

◆

Subtypes

2
Variola major MONDO:0000338
The historically predominant and more virulent smallpox form; typical variola major outbreaks had case-fatality rates of 20% or higher, and ordinary, flat, and hemorrhagic clinical presentations are recorded below as phenotypic and prognostic strata rather than separate disease entries.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"The case-fatality rates for typical variola major outbreaks were 20% or higher."
Documents the high fatality that distinguishes variola major from the milder variola minor/alastrim stratum.
Variola minor MONDO:0004720
A milder smallpox form, also called alastrim, that spread from early twentieth-century foci and was rarely associated with case-fatality rates above 1%.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"Variola minor was rarely associated with case fatality rates of more than 1%, and rates were often lower."
Establishes the low-fatality variola minor/alastrim stratum under the same Variola virus disease.
⚙

Pathophysiology

5
Respiratory-Mucosal Entry and Lymphoreticular Amplification
Inhaled variola seeded the oropharyngeal or respiratory mucosa, infected macrophages, drained along local lymphatics, and replicated in regional lymph nodes, spleen, bone marrow, and distant lymph nodes before symptoms.
macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
viral entry into host cell GO:0046718 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased viral entry into host cell, annotated with symbiont entry into host cell (GO:0046718). GO:0046718 is a biological process from the Gene Ontology. viral genome replication GO:0019079 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased viral genome replication (GO:0019079). GO:0019079 is a biological process from the Gene Ontology.
respiratory tract UBERON:0000065 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in respiratory tract (UBERON:0000065). UBERON:0000065 is an anatomical location from the Uberon multi-species anatomy ontology. mucosa UBERON:0000344 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in mucosa (UBERON:0000344). UBERON:0000344 is an anatomical location from the Uberon multi-species anatomy ontology. lymph node UBERON:0000029 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in lymph node (UBERON:0000029). UBERON:0000029 is an anatomical location from the Uberon multi-species anatomy ontology. spleen UBERON:0002106 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in spleen (UBERON:0002106). UBERON:0002106 is an anatomical location from the Uberon multi-species anatomy ontology. bone marrow UBERON:0002371 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in bone marrow (UBERON:0002371). UBERON:0002371 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Monocytic Cell-Associated Viremia and Systemic Dissemination Local lymphoreticular amplification seeds the blood with leukocyte-associated virus.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"Macrophages were among the early sites/cells of infection, and the virus migrated along the local lymphatic channels and multiplied in regional lymph nodes."
Establishes macrophage infection and lymphatic spread into regional nodes as early events in variola pathogenesis.
Monocytic Cell-Associated Viremia and Systemic Dissemination
Variola spread in monocytes and macrophages to lymphoid tissues and target epithelia, giving a cell-associated viremia that localized virions to dermal capillaries and mucosal surfaces.
macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
dermis UBERON:0002067 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in dermis (UBERON:0002067). UBERON:0002067 is an anatomical location from the Uberon multi-species anatomy ontology. liver UBERON:0002107 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in liver (UBERON:0002107). UBERON:0002107 is an anatomical location from the Uberon multi-species anatomy ontology. lymph node UBERON:0000029 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in lymph node (UBERON:0000029). UBERON:0000029 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Cytopathic Epidermal Vesicle-To-Pustule Formation Virus delivered to dermal vessels infects adjacent basal-layer epidermal cells and starts the vesiculopustular rash.
Hemorrhagic Coagulopathy and Multisystem Failure High viral burdens in target tissues can couple systemic replication to organ dysfunction and coagulation activation.
Fever Secondary viremia precedes the abrupt febrile prodrome.
Headache Secondary viremia precedes the abrupt prodrome with headache.
Show evidence (2 references)
PMID:15477589 SUPPORT Model organism
"After inoculation, variola was disseminated by means of a monocytic cell-associated viremia."
Directly supports cell-associated blood dissemination of variola in the authenticated variola macaque model.
PMID:15477589 SUPPORT Model organism
"Distribution of viral antigens by immunohistochemistry correlated with the presence of replicating viral particles demonstrated by electron microscopy and pathology in the lymphoid tissues, skin, oral mucosa, gastrointestinal tract, reproductive system, and liver."
Defines the disseminated tissues reached by replicating variola in the model.
Variola Immune-Evasion Protein Expression
Variola encodes numerous terminal-region immunomodulatory proteins, including SPICE and a high-affinity CC-chemokine-binding protein, that blunt complement and chemokine-mediated antiviral immunity.
innate immune response GO:0045087 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased innate immune response (GO:0045087). GO:0045087 is a biological process from the Gene Ontology. complement activation GO:0006956 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased complement activation (GO:0006956). GO:0006956 is a biological process from the Gene Ontology.
Downstream
Monocytic Cell-Associated Viremia and Systemic Dissemination Immune evasion increases the probability that local infection proceeds to disseminated infection.
Show evidence (2 references)
PMID:12941397 SUPPORT REVIEW SYNTHESIS Other
"Both SPICE and VCP are similar in structure and function to the family of mammalian complement regulatory proteins, which function to prevent inadvertent injury to adjacent cells and tissues during complement activation."
Supports SPICE as a variola-encoded complement regulatory mimic.
PMID:12941397 SUPPORT REVIEW SYNTHESIS Other
"The second variola protein is the variola virus high-affinity secreted chemokine-binding protein type II (CKBP-II, CBP-II, vCCI), which binds CC-chemokine receptors."
Supports the variola CC-chemokine-binding protein claim in the immune-evasion node description.
Cytopathic Epidermal Vesicle-To-Pustule Formation
Virions localized in dermal small vessels infected basal-layer epidermal cells; cytopathic swelling, vacuolization, cell-membrane rupture, and a neutrophilic vesicle lumen converted lesions from vesicles into pustules and ultimately destructive pock scars.
keratinocyte CL:0000312 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves keratinocyte (CL:0000312). CL:0000312 is a cell type from the Cell Ontology.
viral genome replication GO:0019079 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased viral genome replication (GO:0019079). GO:0019079 is a biological process from the Gene Ontology. inflammatory response GO:0006954 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology.
dermis UBERON:0002067 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in dermis (UBERON:0002067). UBERON:0002067 is an anatomical location from the Uberon multi-species anatomy ontology. skin epidermis UBERON:0001003 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in skin epidermis (UBERON:0001003). UBERON:0001003 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Skin vesicles Epidermal cytopathic injury and edema produce smallpox vesicles.
Centrifugal pustular rash Viral replication and neutrophil-rich vesicle filling generate the synchronous pustular exanthem.
Pitted scarring Destructive pustular lesions heal with the pockmarks seen in survivors.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"As this process continued to progress, polymorphonuclear leukocytes entered the vesicle from the dermis and produced a pustule with disappearance of the septa."
Describes the inflammatory transition from vesicle to pustule in human smallpox skin lesions.
Hemorrhagic Coagulopathy and Multisystem Failure
In lethal disseminated variola, high tissue viral burdens were associated with organ dysfunction, D-dimer evidence of coagulation activation, thrombocytopenia, leukocytosis, and cytokines such as IL-6 and IFN-gamma, matching the hemorrhagic diathesis of severe smallpox.
blood coagulation GO:0007596 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased blood coagulation (GO:0007596). GO:0007596 is a biological process from the Gene Ontology.
Downstream
Hemorrhagic diathesis Coagulation activation and hemorrhagic tissue injury produce the bleeding phenotype of hemorrhagic smallpox.
Show evidence (2 references)
PMID:15477589 SUPPORT Model organism
"High viral burdens in target tissues were associated with organ dysfunction and multisystem failure."
Links disseminated variola replication in target tissues to terminal multisystem failure in the authenticated animal model.
PMID:15477589 SUPPORT Model organism
"Evidence of coagulation cascade activation (D dimers) corroborated histologic evidence of hemorrhagic diathesis."
Supports the coagulation-activation mechanism behind the hemorrhagic branch of severe smallpox.
⬡

Pathograph

Use Group by to collapse related nodes into one box. Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Smallpox Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Blood 1
Hemorrhagic diathesis RARE Abnormal bleeding HP:0001892 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal bleeding (HP:0001892). HP:0001892 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"The rare hemorrhagic-type smallpox was associated with petechiae in the skin and bleeding from the conjunctiva and mucous membranes."
Establishes abnormal bleeding as the defining human manifestation of hemorrhagic smallpox.
PMID:15477589 SUPPORT Model organism
"Evidence of coagulation cascade activation (D dimers) corroborated histologic evidence of hemorrhagic diathesis."
Links variola-driven coagulation activation to hemorrhagic manifestations.
Immune 1
Centrifugal pustular rash COMMON HP:0033605 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pustular rash (HP:0033605). HP:0033605 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"The characteristic smallpox rash had a centrifugal appearance and was most prominent on the face and the extremities, including the palms and soles."
Supports the centrifugal distribution and acral involvement of the rash.
Integument 1
Skin vesicles COMMON HP:0200037 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Skin vesicle (HP:0200037). HP:0200037 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"The process spread to the neighboring cells in the middle layer and was accompanied by profound edema, eventually leading to rupture of cell membranes and formation of a vesicle."
Describes vesicle formation during smallpox skin-lesion morphogenesis.
Metabolism 1
Fever COMMON HP:0001945 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fever (HP:0001945). HP:0001945 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"At the end of this 12- to 14-day incubation period, the patient typically presented with high fever, malaise, and prostration with headache."
Identifies high fever as a core prodromal smallpox manifestation.
Musculoskeletal 1
Pitted scarring COMMON HP:0100699 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Scarring (HP:0100699). HP:0100699 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"Pockmarks were caused by the destruction of sebaceous glands and formation of granulation tissue; they occurred all over the body but were most prominent on the face because of the large number of sebaceous glands located there."
Establishes the mechanism and distribution of permanent pitted scarring in survivors.
Nervous System 1
Headache COMMON HP:0002315 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Headache (HP:0002315). HP:0002315 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"At the end of this 12- to 14-day incubation period, the patient typically presented with high fever, malaise, and prostration with headache."
Identifies headache as part of the smallpox prodrome.
💊

Medical Actions

4
Supportive Care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Platform: Other
Historical smallpox management relied on isolation and supportive care; antibiotics and eye care were added for secondary bacterial or ocular complications when indicated.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"home care seems to be a reasonable approach, since little can be done for the patient other than to offer supportive care."
Documents supportive care as the baseline historical management for patients with smallpox.
Tecovirimat
Action: antiviral agent therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antiviral agent therapy, annotated with Antiviral Therapy (NCIT:C16119). NCIT:C16119 is a clinical intervention from the NCI Thesaurus. Ontology label: Antiviral Therapy NCIT:C16119
Agent: tecovirimat CHEBI:749735 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses tecovirimat (CHEBI:749735). CHEBI:749735 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Oral orthopoxvirus antiviral approved for smallpox under the FDA Animal Rule; it inhibits the conserved p37/VP37 envelope protein and prevents formation and egress of enveloped virions.
Mechanism Target:
INHIBITS Monocytic Cell-Associated Viremia and Systemic Dissemination — p37 inhibition blocks extracellular enveloped virion formation, limiting orthopoxvirus egress and tissue-to-tissue spread.
Show evidence (2 references)
PMID:29972742 SUPPORT Model organism
"Tecovirimat inhibits p37, a protein that is present and highly conserved (approximately 98% amino acid identity) in all orthopoxviruses; the inhibition of p37 prevents the formation and egress of enveloped virions, which are essential for virulence."
Establishes tecovirimat's target and its effect on orthopoxvirus enveloped virion egress.
PMID:29972742 SUPPORT Model organism
"In pilot studies, tecovirimat was shown to provide protective efficacy in multiple small-animal and nonhuman primate models of orthopoxvirus disease."
Records the Animal Rule efficacy basis for tecovirimat rather than an absent human smallpox efficacy trial.
Brincidofovir
Action: antiviral agent therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antiviral agent therapy, annotated with Antiviral Therapy (NCIT:C16119). NCIT:C16119 is a clinical intervention from the NCI Thesaurus. Ontology label: Antiviral Therapy NCIT:C16119
Agent: brincidofovir CHEBI:231032 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses brincidofovir (CHEBI:231032). CHEBI:231032 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Oral lipid-conjugated cidofovir prodrug approved for smallpox under the FDA Animal Rule; it acts as a nucleotide analogue DNA polymerase inhibitor with surrogate efficacy in mousepox and rabbitpox models.
Mechanism Target:
INHIBITS Respiratory-Mucosal Entry and Lymphoreticular Amplification — Brincidofovir inhibits orthopoxvirus DNA synthesis, limiting viral genome replication after host-cell entry.
Show evidence (2 references)
PMID:36688308 SUPPORT REVIEW SYNTHESIS Other
"Brincidofovir adds a second oral agent to treat smallpox, with a different mechanism of action than tecovirimat."
Identifies brincidofovir as an oral smallpox antiviral mechanistically distinct from tecovirimat.
PMID:36688308 SUPPORT REVIEW SYNTHESIS Model organism
"Two surrogate animal models were included in the Food and Drug Administration's (FDA) decision to approve brincidofovir: ectromelia virus in mice and rabbitpox in rabbits."
Describes the surrogate animal models used for the FDA approval decision.
Smallpox vaccination
Action: VaccinationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Vaccination (NCIT:C15346). NCIT:C15346 is a clinical intervention from the NCI Thesaurus. NCIT:C15346
Platform: Vaccine
Vaccinia-based vaccination prevents smallpox and was used with case isolation and contact tracing in ring-vaccination strategies; a prompt post-exposure dose can attenuate or prevent disease.
Mechanism Target:
INHIBITS Respiratory-Mucosal Entry and Lymphoreticular Amplification — Orthopoxvirus immunity blocks productive variola infection after exposure when vaccine-induced responses are present or induced early enough.
Show evidence (1 reference)
PMID:21431786 SUPPORT REVIEW SYNTHESIS Human clinical
"Core components of the public health management of a terrorism attack using smallpox are: vaccination (ring vaccination and mass vaccination), adverse event monitoring, confirmed and suspected smallpox case management, contact management, identifying, tracing, monitoring contacts, and quarantine."
Establishes ring or mass vaccination as a core smallpox countermeasure paired with case and contact management.
📈

Progression

4
Incubation and silent mucosal infection
Incubation: 12-14 days
Respiratory or oropharyngeal acquisition seeded mucosa, macrophages, regional lymph nodes, spleen, bone marrow, and distant lymph nodes before symptoms became apparent.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"This initial infection in the oropharynx and upper respiratory tract was essentially silent, and patients were asymptomatic."
Supports an asymptomatic incubation phase before the febrile prodrome.
Abrupt febrile prodrome
Duration: 2 to 4 days
Secondary viremia preceded sudden high fever, malaise, prostration, and headache near the end of the incubation period.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"At the end of this 12- to 14-day incubation period, the patient typically presented with high fever, malaise, and prostration with headache."
Establishes the timing and core manifestations of the pre-eruptive febrile prodrome.
Centrifugal vesiculopustular rash
Duration: 1 to 2 days
Oral/pharyngeal and cutaneous lesions appeared around day 14 and spread from the face and forearms to the trunk and legs, with most lesions at any body site evolving synchronously.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"The characteristic smallpox rash had a centrifugal appearance and was most prominent on the face and the extremities, including the palms and soles."
Describes the classic centrifugal distribution of the smallpox exanthem.
Scabbing, recovery, or death
Vesicular lesions became pustular, dried into scabs, and healed with pitted scars in survivors; fatal ordinary, flat, or hemorrhagic disease generally ended during the second disease week.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"Once the scabs had separated, patients were no longer infectious"
Defines the endpoint of infectious clinical disease in survivors.
🦠

Infectious Agent

1
Variola virus
Human-restricted orthopoxvirus with a double-stranded DNA genome encoding about 200 proteins, including a large terminal-gene complement devoted to immune evasion.
Variola virus NCBITaxon:10255 NCBI Taxonomy (NCBITaxon)
Show evidence (2 references)
PMID:12941397 SUPPORT REVIEW SYNTHESIS Other
"Variola virus, the causative agent of smallpox, encodes approximately 200 proteins."
Identifies Variola virus as the smallpox agent and summarizes its large coding capacity.
PMID:12941397 SUPPORT REVIEW SYNTHESIS Other
"Over 80 of these proteins are located in the terminal regions of the genome, where proteins associated with host immune evasion are encoded."
Supports the description of a large variola immune-evasion gene complement.
↔️

Transmission

2
Respiratory droplet and aerosol transmission
Transmission usually occurred by infectious droplet nuclei or aerosols expelled from the oropharynx of a person with smallpox, with patients most infectious from rash onset through the first week of the rash.
Show evidence (2 references)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"Smallpox was typically transmitted from person to person via droplet nuclei or aerosols expelled from the oropharynx of infected persons."
Identifies the dominant human-to-human respiratory transmission route.
PMID:21431786 SUPPORT REVIEW SYNTHESIS Human clinical
"Since smallpox patients are most infectious from onset of the rash through the first 7-10 days of the rash, vaccination should be administered promptly within a limited time frame."
Places maximal infectiousness at rash onset and the first 7 to 10 rash days, the window that drives contact tracing and post-exposure vaccination.
Direct lesion and fomite contact transmission
Variola could also be transmitted by direct contact and contaminated clothing or bed linens, but the route was less central than respiratory spread from oropharyngeal lesions.
Show evidence (1 reference)
PMID:16200143 SUPPORT REVIEW SYNTHESIS Human clinical
"Transmission through direct person-to-person contact has also been described. In addition, contaminated clothing or bed linens have been implicated in the spread of the disease."
Documents direct contact and fomite routes in addition to respiratory droplets and aerosols.
{ }

Source YAML

click to show 
name: Smallpox
creation_date: '2026-10-31T06:36:43Z'
category: Infectious Disease
description: >-
  Smallpox is the eradicated systemic orthopoxvirus disease caused by Variola
  virus, a large double-stranded DNA virus restricted to humans. After
  respiratory-mucosal seeding, variola infected macrophages and regional lymph
  nodes, disseminated in a cell-associated viremia to lymphoreticular tissues,
  dermis, mucosa, liver, and other organs, and produced a synchronous
  centrifugal vesiculopustular exanthem whose ordinary, flat, and hemorrhagic
  clinical forms differed sharply in fatality.
disease_term:
  preferred_term: smallpox
  term:
    id: MONDO:0004651
    label: smallpox
parents:
- Orthopoxvirus Infection
- Viral Exanthem
synonyms:
- Variola
- Variola vera
has_subtypes:
- name: Variola major
  subtype_term:
    preferred_term: variola major infectious disease
    term:
      id: MONDO:0000338
      label: variola major infectious disease
  description: >-
    The historically predominant and more virulent smallpox form; typical
    variola major outbreaks had case-fatality rates of 20% or higher, and
    ordinary, flat, and hemorrhagic clinical presentations are recorded below as
    phenotypic and prognostic strata rather than separate disease entries.
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The case-fatality rates for typical variola major outbreaks were 20% or higher.
    explanation: >-
      Documents the high fatality that distinguishes variola major from the
      milder variola minor/alastrim stratum.
- name: Variola minor
  subtype_term:
    preferred_term: variola minor infection
    term:
      id: MONDO:0004720
      label: variola minor infection
  description: >-
    A milder smallpox form, also called alastrim, that spread from early
    twentieth-century foci and was rarely associated with case-fatality rates
    above 1%.
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Variola minor was rarely associated with case fatality rates of more than 1%, and rates were often lower.
    explanation: >-
      Establishes the low-fatality variola minor/alastrim stratum under the
      same Variola virus disease.
infectious_agent:
- name: Variola virus
  description: >-
    Human-restricted orthopoxvirus with a double-stranded DNA genome encoding
    about 200 proteins, including a large terminal-gene complement devoted to
    immune evasion.
  infectious_agent_term:
    preferred_term: Variola virus
    term:
      id: NCBITaxon:10255
      label: Variola virus
  evidence:
  - reference: PMID:12941397
    reference_title: Variola virus immune evasion proteins.
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: >-
      Variola virus, the causative agent of smallpox, encodes approximately 200 proteins.
    explanation: >-
      Identifies Variola virus as the smallpox agent and summarizes its large
      coding capacity.
  - reference: PMID:12941397
    reference_title: Variola virus immune evasion proteins.
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: >-
      Over 80 of these proteins are located in the terminal regions of the genome, where proteins associated with host immune evasion are encoded.
    explanation: >-
      Supports the description of a large variola immune-evasion gene
      complement.
agent_life_cycle:
  description: >-
    Variola virus was maintained by human-to-human spread and had no known
    non-human reservoir or arthropod vector, a biological constraint that helped
    make eradication feasible.
  hosts:
  - preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
    role: sole natural host and transmission reservoir
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, there is no known animal or insect reservoir for smallpox
    explanation: >-
      Establishes the absence of a non-human reservoir or insect vector for
      natural variola maintenance.
transmission:
- name: Respiratory droplet and aerosol transmission
  description: >-
    Transmission usually occurred by infectious droplet nuclei or aerosols
    expelled from the oropharynx of a person with smallpox, with patients most
    infectious from rash onset through the first week of the rash.
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Smallpox was typically transmitted from person to person via droplet nuclei or aerosols expelled from the oropharynx of infected persons.
    explanation: >-
      Identifies the dominant human-to-human respiratory transmission route.
  - reference: PMID:21431786
    reference_title: "Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Since smallpox patients are most infectious from onset of the rash through the first 7-10 days of the rash, vaccination should be administered promptly within a limited time frame.
    explanation: >-
      Places maximal infectiousness at rash onset and the first 7 to 10 rash
      days, the window that drives contact tracing and post-exposure
      vaccination.
- name: Direct lesion and fomite contact transmission
  description: >-
    Variola could also be transmitted by direct contact and contaminated
    clothing or bed linens, but the route was less central than respiratory
    spread from oropharyngeal lesions.
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Transmission through direct person-to-person contact has also been described. In addition, contaminated clothing or bed linens have been implicated in the spread of the disease.
    explanation: >-
      Documents direct contact and fomite routes in addition to respiratory
      droplets and aerosols.
progression:
- phase: Incubation and silent mucosal infection
  incubation_days: 12-14
  notes: >-
    Respiratory or oropharyngeal acquisition seeded mucosa, macrophages,
    regional lymph nodes, spleen, bone marrow, and distant lymph nodes before
    symptoms became apparent.
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This initial infection in the oropharynx and upper respiratory tract was essentially silent, and patients were asymptomatic.
    explanation: >-
      Supports an asymptomatic incubation phase before the febrile prodrome.
- phase: Abrupt febrile prodrome
  duration: 2 to 4 days
  notes: >-
    Secondary viremia preceded sudden high fever, malaise, prostration, and
    headache near the end of the incubation period.
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At the end of this 12- to 14-day incubation period, the patient typically presented with high fever, malaise, and prostration with headache.
    explanation: >-
      Establishes the timing and core manifestations of the pre-eruptive
      febrile prodrome.
- phase: Centrifugal vesiculopustular rash
  duration: 1 to 2 days
  notes: >-
    Oral/pharyngeal and cutaneous lesions appeared around day 14 and spread from
    the face and forearms to the trunk and legs, with most lesions at any body
    site evolving synchronously.
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The characteristic smallpox rash had a centrifugal appearance and was most prominent on the face and the extremities, including the palms and soles.
    explanation: >-
      Describes the classic centrifugal distribution of the smallpox exanthem.
- phase: Scabbing, recovery, or death
  notes: >-
    Vesicular lesions became pustular, dried into scabs, and healed with pitted
    scars in survivors; fatal ordinary, flat, or hemorrhagic disease generally
    ended during the second disease week.
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Once the scabs had separated, patients were no longer infectious
    explanation: >-
      Defines the endpoint of infectious clinical disease in survivors.
pathophysiology:
- name: Respiratory-Mucosal Entry and Lymphoreticular Amplification
  description: >-
    Inhaled variola seeded the oropharyngeal or respiratory mucosa, infected
    macrophages, drained along local lymphatics, and replicated in regional
    lymph nodes, spleen, bone marrow, and distant lymph nodes before symptoms.
  role: trigger
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  locations:
  - preferred_term: respiratory tract
    term:
      id: UBERON:0000065
      label: respiratory tract
  - preferred_term: mucosa
    term:
      id: UBERON:0000344
      label: mucosa
  - preferred_term: lymph node
    term:
      id: UBERON:0000029
      label: lymph node
  - preferred_term: spleen
    term:
      id: UBERON:0002106
      label: spleen
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  biological_processes:
  - preferred_term: viral entry into host cell
    modifier: INCREASED
    term:
      id: GO:0046718
      label: symbiont entry into host cell
  - preferred_term: viral genome replication
    modifier: INCREASED
    term:
      id: GO:0019079
      label: viral genome replication
  downstream:
  - target: Monocytic Cell-Associated Viremia and Systemic Dissemination
    description: >-
      Local lymphoreticular amplification seeds the blood with leukocyte-associated
      virus.
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Macrophages were among the early sites/cells of infection, and the virus migrated along the local lymphatic channels and multiplied in regional lymph nodes.
    explanation: >-
      Establishes macrophage infection and lymphatic spread into regional nodes
      as early events in variola pathogenesis.
- name: Monocytic Cell-Associated Viremia and Systemic Dissemination
  description: >-
    Variola spread in monocytes and macrophages to lymphoid tissues and target
    epithelia, giving a cell-associated viremia that localized virions to dermal
    capillaries and mucosal surfaces.
  role: central_effector
  biological_scale: TISSUE
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  locations:
  - preferred_term: dermis
    term:
      id: UBERON:0002067
      label: dermis
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  - preferred_term: lymph node
    term:
      id: UBERON:0000029
      label: lymph node
  downstream:
  - target: Cytopathic Epidermal Vesicle-To-Pustule Formation
    description: >-
      Virus delivered to dermal vessels infects adjacent basal-layer epidermal
      cells and starts the vesiculopustular rash.
  - target: Hemorrhagic Coagulopathy and Multisystem Failure
    description: >-
      High viral burdens in target tissues can couple systemic replication to
      organ dysfunction and coagulation activation.
  - target: Fever
    description: >-
      Secondary viremia precedes the abrupt febrile prodrome.
  - target: Headache
    description: >-
      Secondary viremia precedes the abrupt prodrome with headache.
  evidence:
  - reference: PMID:15477589
    reference_title: Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      After inoculation, variola was disseminated by means of a monocytic cell-associated viremia.
    explanation: >-
      Directly supports cell-associated blood dissemination of variola in the
      authenticated variola macaque model.
  - reference: PMID:15477589
    reference_title: Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Distribution of viral antigens by immunohistochemistry correlated with the presence of replicating viral particles demonstrated by electron microscopy and pathology in the lymphoid tissues, skin, oral mucosa, gastrointestinal tract, reproductive system, and liver.
    explanation: >-
      Defines the disseminated tissues reached by replicating variola in the
      model.
- name: Variola Immune-Evasion Protein Expression
  description: >-
    Variola encodes numerous terminal-region immunomodulatory proteins,
    including SPICE and a high-affinity CC-chemokine-binding protein, that blunt
    complement and chemokine-mediated antiviral immunity.
  role: amplifier
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: innate immune response
    modifier: DECREASED
    term:
      id: GO:0045087
      label: innate immune response
  - preferred_term: complement activation
    modifier: DECREASED
    term:
      id: GO:0006956
      label: complement activation
  downstream:
  - target: Monocytic Cell-Associated Viremia and Systemic Dissemination
    description: >-
      Immune evasion increases the probability that local infection proceeds to
      disseminated infection.
  evidence:
  - reference: PMID:12941397
    reference_title: Variola virus immune evasion proteins.
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: >-
      Both SPICE and VCP are similar in structure and function to the family of mammalian complement regulatory proteins, which function to prevent inadvertent injury to adjacent cells and tissues during complement activation.
    explanation: >-
      Supports SPICE as a variola-encoded complement regulatory mimic.
  - reference: PMID:12941397
    reference_title: Variola virus immune evasion proteins.
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: >-
      The second variola protein is the variola virus high-affinity secreted chemokine-binding protein type II (CKBP-II, CBP-II, vCCI), which binds CC-chemokine receptors.
    explanation: >-
      Supports the variola CC-chemokine-binding protein claim in the
      immune-evasion node description.
- name: Cytopathic Epidermal Vesicle-To-Pustule Formation
  description: >-
    Virions localized in dermal small vessels infected basal-layer epidermal
    cells; cytopathic swelling, vacuolization, cell-membrane rupture, and a
    neutrophilic vesicle lumen converted lesions from vesicles into pustules and
    ultimately destructive pock scars.
  role: consequence
  biological_scale: TISSUE
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: dermis
    term:
      id: UBERON:0002067
      label: dermis
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
  biological_processes:
  - preferred_term: viral genome replication
    modifier: INCREASED
    term:
      id: GO:0019079
      label: viral genome replication
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Skin vesicles
    description: >-
      Epidermal cytopathic injury and edema produce smallpox vesicles.
  - target: Centrifugal pustular rash
    description: >-
      Viral replication and neutrophil-rich vesicle filling generate the
      synchronous pustular exanthem.
  - target: Pitted scarring
    description: >-
      Destructive pustular lesions heal with the pockmarks seen in survivors.
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As this process continued to progress, polymorphonuclear leukocytes entered the vesicle from the dermis and produced a pustule with disappearance of the septa.
    explanation: >-
      Describes the inflammatory transition from vesicle to pustule in human
      smallpox skin lesions.
- name: Hemorrhagic Coagulopathy and Multisystem Failure
  description: >-
    In lethal disseminated variola, high tissue viral burdens were associated
    with organ dysfunction, D-dimer evidence of coagulation activation,
    thrombocytopenia, leukocytosis, and cytokines such as IL-6 and IFN-gamma,
    matching the hemorrhagic diathesis of severe smallpox.
  role: consequence
  biological_scale: ORGANISM
  biological_processes:
  - preferred_term: blood coagulation
    modifier: INCREASED
    term:
      id: GO:0007596
      label: blood coagulation
  downstream:
  - target: Hemorrhagic diathesis
    description: >-
      Coagulation activation and hemorrhagic tissue injury produce the bleeding
      phenotype of hemorrhagic smallpox.
  evidence:
  - reference: PMID:15477589
    reference_title: Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      High viral burdens in target tissues were associated with organ dysfunction and multisystem failure.
    explanation: >-
      Links disseminated variola replication in target tissues to terminal
      multisystem failure in the authenticated animal model.
  - reference: PMID:15477589
    reference_title: Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Evidence of coagulation cascade activation (D dimers) corroborated histologic evidence of hemorrhagic diathesis.
    explanation: >-
      Supports the coagulation-activation mechanism behind the hemorrhagic
      branch of severe smallpox.
phenotypes:
- name: Fever
  category: Clinical
  frequency: COMMON
  description: High fever was the abrupt prodromal manifestation after secondary viremia.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At the end of this 12- to 14-day incubation period, the patient typically presented with high fever, malaise, and prostration with headache.
    explanation: >-
      Identifies high fever as a core prodromal smallpox manifestation.
- name: Headache
  category: Clinical
  frequency: COMMON
  description: Headache accompanied the high-fever prodrome.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At the end of this 12- to 14-day incubation period, the patient typically presented with high fever, malaise, and prostration with headache.
    explanation: >-
      Identifies headache as part of the smallpox prodrome.
- name: Centrifugal pustular rash
  category: Clinical
  frequency: COMMON
  description: >-
    Deep, synchronous pustules were densest on the face and extremities,
    including palms and soles.
  phenotype_term:
    preferred_term: Pustular rash
    term:
      id: HP:0033605
      label: Pustular rash
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The characteristic smallpox rash had a centrifugal appearance and was most prominent on the face and the extremities, including the palms and soles.
    explanation: >-
      Supports the centrifugal distribution and acral involvement of the rash.
- name: Skin vesicles
  category: Clinical
  frequency: COMMON
  description: >-
    Epidermal cell swelling, vacuolization, edema, and membrane rupture produced
    vesicles before the lesions filled with neutrophils and became pustules.
  phenotype_term:
    preferred_term: Skin vesicle
    term:
      id: HP:0200037
      label: Skin vesicle
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The process spread to the neighboring cells in the middle layer and was accompanied by profound edema, eventually leading to rupture of cell membranes and formation of a vesicle.
    explanation: >-
      Describes vesicle formation during smallpox skin-lesion morphogenesis.
- name: Pitted scarring
  category: Clinical
  frequency: COMMON
  description: >-
    Destructive pustular lesions healed with pockmarks, especially on the face.
  phenotype_term:
    preferred_term: Scarring
    term:
      id: HP:0100699
      label: Scarring
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pockmarks were caused by the destruction of sebaceous glands and formation of granulation tissue; they occurred all over the body but were most prominent on the face because of the large number of sebaceous glands located there.
    explanation: >-
      Establishes the mechanism and distribution of permanent pitted scarring in
      survivors.
- name: Hemorrhagic diathesis
  category: Clinical
  context: hemorrhagic smallpox
  frequency: RARE
  phenotype_term:
    preferred_term: Abnormal bleeding
    term:
      id: HP:0001892
      label: Abnormal bleeding
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The rare hemorrhagic-type smallpox was associated with petechiae in the skin and bleeding from the conjunctiva and mucous membranes.
    explanation: >-
      Establishes abnormal bleeding as the defining human manifestation of
      hemorrhagic smallpox.
  - reference: PMID:15477589
    reference_title: Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Evidence of coagulation cascade activation (D dimers) corroborated histologic evidence of hemorrhagic diathesis.
    explanation: >-
      Links variola-driven coagulation activation to hemorrhagic manifestations.
treatments:
- name: Supportive Care
  description: >-
    Historical smallpox management relied on isolation and supportive care;
    antibiotics and eye care were added for secondary bacterial or ocular
    complications when indicated.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:16200143
    reference_title: "Smallpox and biological warfare: a disease revisited."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      home care seems to be a reasonable approach, since little can be done for the patient other than to offer supportive care.
    explanation: >-
      Documents supportive care as the baseline historical management for
      patients with smallpox.
- name: Tecovirimat
  description: >-
    Oral orthopoxvirus antiviral approved for smallpox under the FDA Animal Rule;
    it inhibits the conserved p37/VP37 envelope protein and prevents formation
    and egress of enveloped virions.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: antiviral agent therapy
    term:
      id: NCIT:C16119
      label: Antiviral Therapy
    therapeutic_agent:
    - preferred_term: tecovirimat
      term:
        id: CHEBI:749735
        label: tecovirimat
  target_mechanisms:
  - target: Monocytic Cell-Associated Viremia and Systemic Dissemination
    treatment_effect: INHIBITS
    description: >-
      p37 inhibition blocks extracellular enveloped virion formation, limiting
      orthopoxvirus egress and tissue-to-tissue spread.
  evidence:
  - reference: PMID:29972742
    reference_title: Oral Tecovirimat for the Treatment of Smallpox.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Tecovirimat inhibits p37, a protein that is present and highly conserved (approximately 98% amino acid identity) in all orthopoxviruses; the inhibition of p37 prevents the formation and egress of enveloped virions, which are essential for virulence.
    explanation: >-
      Establishes tecovirimat's target and its effect on orthopoxvirus enveloped
      virion egress.
  - reference: PMID:29972742
    reference_title: Oral Tecovirimat for the Treatment of Smallpox.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In pilot studies, tecovirimat was shown to provide protective efficacy in multiple small-animal and nonhuman primate models of orthopoxvirus disease.
    explanation: >-
      Records the Animal Rule efficacy basis for tecovirimat rather than an
      absent human smallpox efficacy trial.
- name: Brincidofovir
  description: >-
    Oral lipid-conjugated cidofovir prodrug approved for smallpox under the FDA
    Animal Rule; it acts as a nucleotide analogue DNA polymerase inhibitor with
    surrogate efficacy in mousepox and rabbitpox models.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: antiviral agent therapy
    term:
      id: NCIT:C16119
      label: Antiviral Therapy
    therapeutic_agent:
    - preferred_term: brincidofovir
      term:
        id: CHEBI:231032
        label: Brincidofovir
  target_mechanisms:
  - target: Respiratory-Mucosal Entry and Lymphoreticular Amplification
    treatment_effect: INHIBITS
    description: >-
      Brincidofovir inhibits orthopoxvirus DNA synthesis, limiting viral genome
      replication after host-cell entry.
  evidence:
  - reference: PMID:36688308
    reference_title: "Brincidofovir: A Novel Agent for the Treatment of Smallpox."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: >-
      Brincidofovir adds a second oral agent to treat smallpox, with a different mechanism of action than tecovirimat.
    explanation: >-
      Identifies brincidofovir as an oral smallpox antiviral mechanistically
      distinct from tecovirimat.
  - reference: PMID:36688308
    reference_title: "Brincidofovir: A Novel Agent for the Treatment of Smallpox."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Two surrogate animal models were included in the Food and Drug Administration's (FDA) decision to approve brincidofovir: ectromelia virus in mice and rabbitpox in rabbits.
    explanation: >-
      Describes the surrogate animal models used for the FDA approval decision.
- name: Smallpox vaccination
  description: >-
    Vaccinia-based vaccination prevents smallpox and was used with case
    isolation and contact tracing in ring-vaccination strategies; a prompt
    post-exposure dose can attenuate or prevent disease.
  therapeutic_modality: VACCINE
  treatment_term:
    preferred_term: Vaccination
    term:
      id: NCIT:C15346
      label: Vaccination
  target_mechanisms:
  - target: Respiratory-Mucosal Entry and Lymphoreticular Amplification
    treatment_effect: INHIBITS
    description: >-
      Orthopoxvirus immunity blocks productive variola infection after exposure
      when vaccine-induced responses are present or induced early enough.
  evidence:
  - reference: PMID:21431786
    reference_title: "Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Core components of the public health management of a terrorism attack using smallpox are: vaccination (ring vaccination and mass vaccination), adverse event monitoring, confirmed and suspected smallpox case management, contact management, identifying, tracing, monitoring contacts, and quarantine.
    explanation: >-
      Establishes ring or mass vaccination as a core smallpox countermeasure
      paired with case and contact management.
review_notes: >-
  Deliberately lumped. This entry keeps variola major, variola minor/alastrim,
  ordinary, modified, flat, and hemorrhagic smallpox in one Variola virus disease
  entry because they are virulence or clinical-severity strata of the same
  historical pathogen-syndrome pair, not separate agent-syndrome entities.
  Duplicate preflight searched MONDO:0004651, smallpox, variola, variola major,
  and variola minor across current origin/main, all pull requests, and all issues
  before issue 16149 claimed the term.
references:
- reference: PMID:12941397
  title: Variola virus immune evasion proteins.
  findings: []
- reference: PMID:15477589
  title: Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.
  findings: []
- reference: PMID:16200143
  title: "Smallpox and biological warfare: a disease revisited."
  findings: []
- reference: PMID:21431786
  title: "Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications."
  findings: []
- reference: PMID:29972742
  title: Oral Tecovirimat for the Treatment of Smallpox.
  findings: []
- reference: PMID:36688308
  title: "Brincidofovir: A Novel Agent for the Treatment of Smallpox."
  findings: []
📚

References & Deep Research

References

6
PMID:12941397
Variola virus immune evasion proteins.
No top-level findings curated for this source.
PMID:15477589
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.
No top-level findings curated for this source.
PMID:16200143
Smallpox and biological warfare: a disease revisited.
No top-level findings curated for this source.
PMID:21431786
Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications.
No top-level findings curated for this source.
PMID:29972742
Oral Tecovirimat for the Treatment of Smallpox.
No top-level findings curated for this source.
PMID:36688308
Brincidofovir: A Novel Agent for the Treatment of Smallpox.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Smallpox · 2026-10-31T07:01:26Z · View source

Created a de-novo MONDO:0004651 infectious-disease entry from the OpenScientist Smallpox deep-research report and PubMed reference validation. Added the Variola virus infectious agent, human-only life cycle, respiratory and direct-contact transmission, variola major/minor subtype rows, clinical progression phases, five mechanism nodes spanning respiratory entry through hemorrhagic coagulopathy, HPO phenotypes, antiviral and vaccination treatment records, PubMed reference caches, and term-cache rows.

OpenScientist ▸
Smallpox (Variola virus disease) — Comprehensive Disease Characterization Report
openscientist-autonomous 32 citations 2026-10-30T23:53:21.052240

Smallpox (Variola virus disease) — Comprehensive Disease Characterization Report

Disease: Smallpox MONDO ID: MONDO:0004651 Category: Infectious Disease Causal agent: Variola virus (VARV), an Orthopoxvirus (NCBI Taxon 10255) — no human causal gene

Summary

Smallpox is not a genetic disease. Despite the "causal gene" field of the research template, smallpox (MONDO:0004651) is an acute, systemic, human-restricted infectious disease caused by the Variola virus (VARV), a large (~186 kb) double-stranded DNA virus of the genus Orthopoxvirus (family Poxviridae). VARV encodes ~200 proteins and replicates entirely in the host-cell cytoplasm; more than 80 of its proteins — concentrated in the terminal regions of the genome — carry out host immune-evasion functions rather than classic housekeeping roles PMID: 12941397. The disease was the first (and to date only human disease) to be deliberately eradicated: the last endemic natural case occurred in Somalia in 1977, and the World Health Organization certified global eradication in 1980 PMID: 42135325. Because VARV stocks are retained and routine vaccination ceased decades ago, leaving populations immunologically naïve, smallpox remains a Category A biodefense concern PMID: 42576544.

Pathogenesis proceeds from respiratory-mucosal entry, through a monocyte-associated cell-associated viremia that disseminates virus to lymphoid tissues, skin, oral mucosa, gastrointestinal tract, reproductive organs and liver, to a characteristic synchronous, deep-seated, centrifugal vesiculopustular rash PMID: 15477589. Severe (flat and hemorrhagic) forms involve cytokine-driven coagulopathy and multi-organ failure. Clinical outcome tracks disease type: discrete ordinary smallpox ~10% case-fatality, confluent ~50–75%, and flat/hemorrhagic forms >95%, with variola major averaging ~30% in the unvaccinated and variola minor (alastrim) <1% PMID: 42135325, PMID: 42576544.

Smallpox was eradicated through ring vaccination and isolation using live vaccinia-based vaccines; post-exposure vaccination within ~3–4 days can prevent or attenuate disease. Modern countermeasures comprise the vaccinia-based vaccines ACAM2000 (replication-competent) and MVA-BN/JYNNEOS (non-replicating), plus two FDA Animal-Rule antivirals: tecovirimat (TPOXX; inhibits the VP37/p37 envelope protein required for extracellular virion egress) and brincidofovir (Tembexa; a lipid-conjugated oral prodrug of the DNA-polymerase inhibitor cidofovir) PMID: 41740032, PMID: 36688308.

1. Disease Information

Smallpox is an acute contagious systemic viral illness caused by the Variola virus. Humans are the only natural host — there is no animal reservoir, a feature that made global eradication feasible.

Key identifiers:

Resource Identifier
MONDO MONDO:0004651
ICD-10 B03
ICD-11 1E70
MeSH D012899 (Smallpox)
NCBI Taxonomy (agent) Variola virus, Taxon 10255
OMIM Not applicable (not a Mendelian genetic disorder)
Orphanet Not a rare genetic disease; historical infectious disease

Synonyms: Variola; variola vera; variola major; variola minor (alastrim); Variola virus infectious disease; ordinary smallpox.

Information source type: Disease-level aggregated resources (WHO eradication records, historical clinical series, and modern animal-model and vaccinology studies), not individual-patient EHR data — no new natural cases have occurred since 1977. The ICD2Vec framework notably identified smallpox (ICD-10 B03) among diseases semantically similar to COVID-19 PMID: 37054960.

2. Etiology

Primary cause — infectious: Variola virus, an Orthopoxvirus closely related to vaccinia, cowpox and monkeypox (mpox) viruses. VARV is a large dsDNA virus (~186 kb, ~200 genes) that replicates in the cytoplasm within viral "factories." There is no genetic, toxic, or metabolic etiology — smallpox is entirely virus-driven PMID: 12941397.

Risk factors (environmental/behavioral): - Close contact with an infected person (respiratory droplets, direct contact with lesions or contaminated fomites such as bedding). - Lack of prior vaccination (populations born after ~1980 are largely immunologically naïve) PMID: 42576544. - Crowding, household exposure, and healthcare settings pre-eradication. - Pregnancy and immunocompromise historically predisposed to more severe (including hemorrhagic) disease.

Genetic risk factors: No validated human host-susceptibility loci are established for VARV, reflecting the absence of modern population studies (eradicated before genomic epidemiology). Host genetic variation in innate/adaptive immune genes is plausible but not characterized.

Protective factors: Prior smallpox vaccination (vaccinia immunity) is strongly protective and conferred durable, decades-long protection (see Finding F007). Historical smallpox vaccination still provides ~70% residual cross-protection against the related mpox virus decades later PMID: 39176988.

Gene–environment interactions: Not characterized for smallpox. The dominant determinant of outcome was vaccination status and clinical form, not host genotype.

3. Phenotypes

Smallpox follows a stereotyped clinical course after a 7–19 day incubation (typically 10–14 days). Key phenotypes:

Phenotype Type Characteristics Suggested HPO term
Febrile prodrome (high fever, malaise, headache, backache) Symptom Acute onset, precedes rash by 2–4 days; severe HP:0001945 (Fever)
Enanthem (oral/pharyngeal mucosal lesions) Clinical sign Appears with/just before skin rash; infectious HP:0000164 (Oral mucosa abnormality)
Synchronous vesiculopustular rash Physical manifestation Deep-seated, firm, "pearl-like" pustules all at the same stage; centrifugal (face/extremities > trunk) HP:0200041 (Vesicle); HP:0000987 (Atypical scarring of skin)
Lesions on palms and soles Physical manifestation Characteristic, distinguishes from varicella —
Umbilicated pustules Physical manifestation Central depression HP:0200039 (Papule)
Pitted/pock scarring Physical manifestation (sequela) Permanent, disfiguring; healed survivors HP:0000987
Hemorrhagic diathesis (flat/hemorrhagic forms) Laboratory/clinical Thrombocytopenia, D-dimer elevation, mucosal bleeding HP:0001892 (Abnormal bleeding); HP:0001873 (Thrombocytopenia)
Leukocytosis Laboratory abnormality Profound in lethal disease (macaque model) HP:0001974 (Leukocytosis)

The synchronous progression (all lesions evolving together: macule → papule → vesicle → pustule → crust) and the centrifugal distribution are the classic phenotypic signatures distinguishing smallpox from chickenpox (varicella), in which lesions appear in crops at different stages.

WHO (Rao) clinical types and frequency among affected individuals: - Ordinary (~90%) - Modified (in partially immune/vaccinated) - Flat/malignant (rare, >95% fatal) - Hemorrhagic (rare, >95% fatal) - Variola minor (alastrim; <1% fatal)

Quality-of-life impact: Acute disease was debilitating and often fatal; survivors suffered permanent pockmark scarring, blindness from corneal involvement, and limb deformities. Standardized QoL instruments (EQ-5D/SF-36) were not applied historically.

4. Genetic / Molecular Information

This is not a host-genetic disease. The relevant "genetics" are those of the viral genome:

  • Genome: ~186 kb linear dsDNA with covalently closed hairpin termini and inverted terminal repeats; ~200 open reading frames; cytoplasmic replication PMID: 12941397.
  • Immune-evasion gene complement: >80 proteins in the terminal genome regions encode host-interaction/immune-evasion functions. Orthopoxviruses carry the largest antidefense-gene complement of any animal virus family, shaped by ancient gene capture and recent gene loss PMID: 34253028.
  • Phylogeny (viral strain variation): Analysis of ~48 VARV genomes resolves two clades — Clade 1 (variola major variants) and Clade 2 (West African and variola minor/alastrim strains) — mapping onto the virulence divide PMID: 28749451. Ancient genomes (a ~400-year-old Lithuanian mummy; 60-/160-year-old Prague museum specimens) fall basal or represent extinct European lineages, confirming deep evolutionary history PMID: 28749451, PMID: 33022266.

Human host genes: No causal human gene, HGNC entry, ClinVar variant, gnomAD allele frequency, or chromosomal abnormality applies. Sections on pathogenic variants, modifier genes, epigenetics, and chromosomal abnormalities are not applicable to this infectious disease.

5. Environmental Information

Infectious agent: Variola virus (NCBI Taxon 10255), genus Orthopoxvirus, family Poxviridae. Transmitted human-to-human via respiratory droplets/aerosols, direct contact with lesion material, and contaminated fomites (bedding, clothing). Patients are most infectious from rash onset through the first 7–10 days of rash PMID: 21431786.

Environmental/lifestyle factors: No toxins, radiation, diet, or occupational chemical exposures cause smallpox. Crowding and inadequate isolation facilitated spread historically. The disease has no environmental reservoir — eradication was possible precisely because VARV cannot persist outside humans.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating infection → clinical manifestation)

  1. Inhalation of VARV-laden droplets/aerosol deposits virus on the oropharyngeal/respiratory mucosa, which leads to infection of mucosal epithelial cells and local macrophages (demonstrated in the aerosol monkeypox macaque surrogate: early lung replication) PMID: 25653439.
  2. Viral entry into host cells via a multi-protein, glycosaminoglycan (GAG)-dependent attachment system — ~4 mature-virion membrane proteins bind heparan/chondroitin sulfate or laminin — followed by an 11–12-protein entry-fusion complex that fuses at the plasma membrane or in acidified endosomes after macropinocytosis; this results in cytoplasmic release of the viral core PMID: 22754644, PMID: 38321165.
  3. Infected migratory monocytes/macrophages carry virus to draining lymph nodes, establishing a monocyte-associated cell-associated viremia that leads to systemic dissemination (primary viremia) PMID: 15477589.
  4. Viral immune-evasion proteins (>80 encoded) suppress host defense: the secreted complement regulator SPICE (smallpox inhibitor of complement enzymes) anchors to cells via heparan/chondroitin-sulfate GAGs and inhibits complement at the C3 convertase step via combined decay-acceleration and factor-I cofactor activity, with human-pathway selectivity — molecularly mirroring VARV's human host-restriction; chemokine- and cytokine-binding proteins further blunt innate immunity PMID: 18768877, PMID: 19667083, PMID: 28724763.
  5. Secondary viremia seeds the skin, oral mucosa, GI tract, reproductive organs, and liver, where viral replication in dermal/epithelial cells produces the enanthem and the deep-seated vesiculopustular exanthem PMID: 15477589.
  6. In severe disease, massive viral replication and a dysregulated cytokine response (elevated IL-1ra, IL-6, IFN-γ in the aerosol model) drive coagulation activation (thrombocytopenia, D-dimer elevation), depletion of T-cell-dependent lymphoid areas, and multi-organ hemorrhagic diathesis — the lethal flat/hemorrhagic phenotype PMID: 15477589, PMID: 25653439.

Branch point

    VARV respiratory entry
            │
 monocyte-associated viremia
            │
    ┌───────────────┴───────────────┐
   Controlled replication            Uncontrolled replication +
   + adaptive immunity                cytokine storm + coagulopathy
    │                                 │
   Ordinary/discrete rash            Flat / hemorrhagic smallpox
   (CFR ~10-30%)                      (CFR >95%)

Mechanistic detail by category

  • Molecular pathways: GAG-mediated attachment (heparan sulfate CHEBI:28815; chondroitin sulfate); complement cascade inhibition at C3/C5 convertase; interferon and chemokine signaling suppression.
  • Protein dysfunction (viral, not host): The chondroitin-sulfate-binding protein D8 bends the host membrane to drive fusion-pore formation PMID: 38321165. SPICE achieves complement inhibition equal to or greater than host regulators PMID: 18768877.
  • Immune system involvement: Complement evasion (SPICE), impaired NK function, lymphopenia, and cytokine storm are central; the host response is both protective and, when dysregulated, pathogenic.
  • Tissue-damage mechanisms: Direct cytopathic viral replication in epithelium plus immune-mediated injury; hemorrhagic forms involve coagulopathy and endothelial compromise.

Suggested GO terms: GO:0019062 (virion attachment to host cell), GO:0046718 (viral entry into host cell), GO:0052170 (symbiont-mediated suppression of host innate immune response), GO:0030449 (regulation of complement activation), GO:0001816 (cytokine production). Suggested CL terms: CL:0000576 (monocyte), CL:0000235 (macrophage), CL:0000312 (keratinocyte), CL:0000084 (T cell).

7. Anatomical Structures Affected

Organ/system level: - Primary: Skin (UBERON:0002097) and mucous membranes — oral/pharyngeal mucosa (UBERON:0000344), respiratory tract (UBERON:0000065, entry site). - Lymphoreticular system: lymph nodes (UBERON:0000029), spleen (UBERON:0002106), tonsil (UBERON:0002372) — sites of viral amplification PMID: 15477589, PMID: 25653439. - Secondary: Gastrointestinal tract (UBERON:0000160), liver (UBERON:0002107), reproductive organs, eyes (corneal scarring → blindness), and in severe disease, systemic involvement with coagulopathy. - Body systems: integumentary, respiratory, lymphatic/immune, hematologic, hepatic.

Tissue/cell level: Epithelial tissue (epidermis, mucosal epithelium); dermal fibroblasts; monocytes/macrophages (vehicle of dissemination; CL:0000576/CL:0000235); depletion of T-cell-dependent lymphoid zones.

Subcellular level: Viral replication occurs in cytoplasmic viral factories (GO:0030430, host cytoplasm) — distinctively, poxviruses do not require the nucleus for replication. Virion assembly and envelopment traverse the ER/Golgi and plasma-membrane compartments.

Localization/lateralization: Rash is bilateral and symmetric, centrifugal (denser on face, forearms, hands, feet, including palms and soles).

8. Temporal Development

  • Onset: Acute. Incubation 7–19 days (commonly 10–14), followed by abrupt febrile prodrome lasting 2–4 days, then rash.
  • Stages: (1) Incubation (asymptomatic); (2) prodrome (fever, prostration); (3) early rash/enanthem (most infectious); (4) pustular rash; (5) scabbing/resolution or death. The aerosol macaque model documented temperature peak at day 6 with concurrent skin pox PMID: 25653439.
  • Progression rate: Rapid, self-limited over ~3–4 weeks in survivors; crusts separate leaving pitted scars. Death in fatal cases typically occurred in the second week.
  • Course pattern: Monophasic acute illness (not relapsing/chronic). No chronic or latent carrier state.
  • Infectious period: From rash onset through the first 7–10 days of rash PMID: 21431786.
  • Critical intervention window: Post-exposure vaccination within ~3–4 days can prevent or attenuate disease — the basis for ring vaccination PMID: 21431786.

9. Inheritance and Population

  • Inheritance: None — infectious, not heritable. Sections on penetrance, expressivity, anticipation, mosaicism, founder effects, consanguinity, and carrier frequency are not applicable.
  • Epidemiology (historical): Before eradication, smallpox was endemic worldwide and caused an estimated ~300 million deaths in the 20th century alone. Last endemic natural case: Somalia, October 1977; WHO certified eradication in 1980 PMID: 42135325. Current incidence/prevalence: zero (eradicated).
  • Geographic distribution: Formerly global. The two viral clades map geographically — Clade 2 includes West African and alastrim (variola minor) strains PMID: 28749451.
  • Sex ratio: No strong sex predilection; outcome driven by vaccination status, age, pregnancy, and clinical form rather than sex.
  • Age distribution: All ages susceptible when unvaccinated; young children and the elderly had higher case-fatality historically.

10. Diagnostics

Clinical diagnosis (historical): Based on the characteristic synchronous, deep-seated, centrifugal vesiculopustular rash with palm/sole involvement and febrile prodrome.

Laboratory confirmation: - PCR / real-time PCR on lesion material — the modern confirmatory standard for orthopoxvirus/VARV identification. - Electron microscopy — brick-shaped orthopoxvirus virions in vesicle fluid (identifies genus, not species). - Serology / immunohistochemistry — supportive; IHC localizes viral antigen in tissue (used in the macaque model) PMID: 15477589. - Viral culture and genome sequencing for definitive speciation and clade assignment PMID: 28749451.

Laboratory abnormalities in severe disease: profound leukocytosis, thrombocytopenia, elevated creatinine, and D-dimer elevation (coagulation activation) PMID: 15477589.

Clinical criteria: WHO case definition (acute onset of fever ≥38.3°C followed by firm, deep-seated vesicles/pustules at the same stage of development).

Differential diagnosis: Chickenpox (varicella — superficial, pleomorphic lesions in crops, central distribution, spares palms/soles), mpox/monkeypox (prominent lymphadenopathy, milder course), disseminated herpes zoster, drug eruptions, and other vesicular illnesses PMID: 41600835.

Genetic testing: Not applicable (no host gene). "Genetic testing" here means viral genome sequencing for strain/clade confirmation.

Screening: No population screening applies (eradicated disease); surveillance focuses on bioterrorism preparedness and differentiating from mpox.

11. Outcome / Prognosis

Case fatality by clinical type (unvaccinated):

Clinical form Approximate frequency Case-fatality rate
Discrete ordinary Common ~10%
Confluent ordinary — ~50–75%
Flat (malignant) Rare >95%
Hemorrhagic Rare >95%
Variola major (overall) ~90% of cases ~30%
Variola minor (alastrim) — <1%

Sources: PMID: 42135325, PMID: 42576544.

Recovery: Survivors develop lifelong immunity. Sequelae include permanent pockmark scarring (often facial, disfiguring), blindness from keratitis/corneal scarring, and occasionally limb deformities (osteomyelitis variolosa) or encephalitis.

Prognostic factors: Clinical type (flat/hemorrhagic forms near-uniformly fatal), vaccination status (vaccinated patients had milder "modified" disease), age (worse in very young and elderly), pregnancy (predisposed to hemorrhagic form), and extent of confluent rash. Early hemorrhagic manifestations and marked thrombocytopenia/coagulopathy portended death PMID: 15477589.

12. Treatment

Historically, treatment was supportive only (fluids, nutrition, wound care, prevention/treatment of secondary bacterial infection). Modern FDA-approved specific antivirals, developed under the Animal Rule (human efficacy trials being impossible/unethical for an eradicated disease):

Drug Trade name Target / mechanism Basis of approval NCIT
Tecovirimat TPOXX Inhibits orthopoxvirus VP37/p37 envelope protein required for extracellular (enveloped) virion formation/egress NHP mpox & rabbitpox models NCIT:C171621 (Tecovirimat)
Brincidofovir Tembexa Lipid-conjugated oral prodrug of cidofovir; viral DNA-polymerase inhibitor Ectromelia (mouse) & rabbitpox (rabbit) surrogate models NCIT:C97660 (Brincidofovir)
  • Tecovirimat is "approved for smallpox treatment under the Food and Drug Administration Animal Rule on the basis of efficacy in nonhuman primate models of mpox" PMID: 41740032.
  • "Brincidofovir adds a second oral agent to treat smallpox, with a different mechanism of action than tecovirimat" PMID: 36688308.
  • Cidofovir (parent compound; DNA-polymerase inhibitor) has activity against orthopoxviruses and reduces MPXV replication in mouse respiratory tract PMID: 39243894; it is nephrotoxic and not formally smallpox-approved.

Important caveat on efficacy evidence: In a randomized human mpox (clade II) trial, tecovirimat showed no benefit over placebo (83% vs 84% lesion resolution by day 29), underscoring that smallpox approval rests on animal efficacy data, not human smallpox trials, and that antiviral efficacy against human orthopoxvirus disease remains uncertain PMID: 41740032. Emerging tecovirimat resistance (VP37 mutations) is a further concern, motivating combination regimens PMID: 41038284.

Pharmacogenomics / gene therapy / cell therapy / targeted & immunotherapy: Not applicable in the conventional oncologic/genetic sense; the "targeted therapy" here is the host- and virus-directed small-molecule antivirals above.

13. Prevention

Prevention is the triumph of smallpox control and the reason for its eradication.

Primary prevention — vaccination (vaccinia-based, cross-protective):

Vaccine Platform Key properties
Dryvax (1st gen) Replication-competent vaccinia (calf lymph) Eradication-era vaccine; durable immunity 40–80 years PMID: 40311645
ACAM2000 (2nd gen) Clonal replication-competent vaccinia Current US stockpile; defined risk profile PMID: 42576544
MVA-BN / JYNNEOS (3rd gen) Non-replicating Modified Vaccinia Ankara Safer for immunocompromised; sustained memory ≥5 years with strong booster effect PMID: 41819114
  • Edward Jenner's cowpox-based vaccination (1796) founded the field of immunization and underpinned eradication PMID: 39371745.
  • Protective immunity must target both virion forms — the intracellular mature virion (IMV) and extracellular enveloped virion (EEV) — because of the dual-virion architecture of orthopoxviruses; rational vaccines target IMV antigens (A27/L1 ≈ A29L/M1R) and EEV antigens (B5/A33 ≈ B6R/A35R) PMID: 41941064. A DNA "4pox" vaccine targeting L1, A27, B5, A33 protected rabbits against lethal aerosol rabbitpox PMID: 34851148.

Public-health strategy: Ring vaccination plus case isolation — identifying cases and vaccinating contacts and contacts-of-contacts — eradicated the disease. Post-exposure vaccination within ~3–4 days prevents/attenuates illness PMID: 21431786.

Vaccine safety (serious adverse events of replication-competent vaccinia): postvaccinial encephalitis, progressive vaccinia, eczema vaccinatum, and generalized vaccinia — "vaccination can accompany complications, such as postvaccinial encephalitis, progressive vaccinia, eczema vaccinatum, and generalized vaccinia" PMID: 21431786. Death rates are strain-dependent: ~1.4 deaths/million for NYCBH strain vs ~8.4/million for Lister strain PMID: 16933957. Myocarditis and dilated cardiomyopathy are additional recognized risks PMID: 26004568. MVA-BN avoids these replication-associated risks, making it suitable for immunocompromised recipients.

14. Other Species / Natural Disease

  • Host range: VARV is strictly human-restricted with no animal reservoir — the decisive biological fact enabling eradication. SPICE's human-complement selectivity (vs vaccinia VCP's bovine-complement preference) is a molecular correlate of this host-restriction PMID: 28724763.
  • Zoonotic potential: None for VARV itself. However, related orthopoxviruses are zoonotic — monkeypox/mpox virus (from African rodents/primates), cowpox, and novel orthopoxviruses (e.g., a distinct lineage in an Alaska resident) cause human disease, and rising incidence is attributed to waning post-smallpox-vaccination immunity PMID: 28329402.
  • Comparative biology: Orthopoxviruses share genome architecture and immune-evasion gene families shaped by ancient gene capture and recent gene loss PMID: 34253028. Avipoxviruses (fowlpox, penguin/pigeon poxviruses) are more distantly related but carry VARV B22R orthologues, illustrating deep poxvirus gene conservation PMID: 24919868.

15. Model Organisms

Because VARV infects only humans and live virus is restricted to two WHO-authorized high-containment laboratories, surrogate models are essential and form the regulatory basis for antiviral and vaccine approval:

Model system Virus used Use / phenotype recapitulation Reference
Cynomolgus macaque Variola (Harper/India strains), IV high dose Reproduces monocyte-associated viremia, lymphoid/skin/mucosal/GI/liver dissemination, leukocytosis, thrombocytopenia, D-dimer rise, hemorrhagic diathesis; requires non-physiologic high dose PMID: 15477589
Cynomolgus macaque Aerosolized monkeypox Recapitulates respiratory entry → lung replication → spread to tonsil/spleen/nodes/colon by day 4 → fever peak day 6 with skin pox; IL-1ra/IL-6/IFN-γ surge PMID: 25653439
Rabbit Rabbitpox (aerosol) Models respiratory, low-dose exposure akin to natural smallpox; used for 4pox DNA vaccine and tecovirimat efficacy PMID: 34851148
Mouse Ectromelia (mousepox); intranasal MPXV Brincidofovir approval surrogate; cidofovir/brincidofovir reduce respiratory viral load PMID: 36688308, PMID: 39243894
In vitro Vaccinia (prototype) Entry/fusion mechanics (D8, entry-fusion complex), gene function via transient complementation PMID: 22754644, PMID: 31240675

Model limitations: No model fully reproduces the human-restricted, low-dose respiratory transmission and the full spectrum of human clinical forms; macaque variola requires large intravenous inocula, and mpox/rabbitpox/mousepox are related-but-distinct viruses. This surrogacy is precisely why antivirals are approved under the Animal Rule rather than on human efficacy.

Key Findings (Consolidated)

F001 — Smallpox is caused by Variola virus, not a human gene; eradicated 1980

VARV (NCBI Taxon 10255) is a ~186 kb dsDNA Orthopoxvirus encoding ~200 proteins and replicating in the cytoplasm. Over 80 proteins in the genome terminal regions carry immune-evasion functions. WHO certified eradication in 1980; retained stocks and loss of population immunity sustain biodefense concern. "Smallpox, eradicated globally in 1980, remains a major biodefense concern due to retained Variola virus stocks and the absence of population immunity following cessation of routine vaccination." PMID: 42576544; PMID: 12941397.

F002 — Pathogenesis: monocyte-associated viremia → lymphoid dissemination → multi-organ hemorrhagic diathesis

"After inoculation, variola was disseminated by means of a monocytic cell-associated viremia" with antigen in lymphoid tissue, skin, oral mucosa, GI tract, reproductive system, and liver PMID: 15477589. The aerosol mpox macaque model documents the temporal sequence from respiratory entry to systemic spread and rash PMID: 25653439.

F003 — Countermeasures: tecovirimat + brincidofovir (Animal Rule) plus ACAM2000/MVA-BN vaccines

Tecovirimat targets VP37/p37 (egress); brincidofovir is an oral DNA-polymerase inhibitor prodrug — both FDA-approved via animal models PMID: 41740032, PMID: 36688308. Vaccinia vaccination carries rare serious adverse events (~1 death/million) PMID: 21431786, PMID: 16933957.

F004 — Clinical classification & case fatality

Ordinary (~90%), modified, flat, hemorrhagic forms plus variola minor; CFR ~10% (discrete) to >95% (flat/hemorrhagic); variola major ~30%, minor <1%. Last natural case 1977; eradication 1980 PMID: 42135325, PMID: 42576544, PMID: 21431786.

F005 — Two-clade VARV phylogeny mapping onto the virulence divide

"Based on the genomes of 48 strains, two clades are differentiated: Clade 1 includes variants of variola major, and clade 2 includes West African and variola minor (Alastrim) strains" PMID: 28749451. Orthopoxviruses have the largest antidefense-gene complement of any animal virus family PMID: 34253028.

F006 — GAG-dependent entry machinery; SPICE inhibits human complement at C3 convertase

"Four viral proteins associated with the MV membrane facilitate attachment by binding to glycosaminoglycans or laminin on the cell surface" PMID: 22754644. SPICE anchors via heparan/chondroitin sulfate and inhibits complement at the C3 convertase step PMID: 18768877, with human-pathway selectivity mirroring host restriction PMID: 28724763.

F007 — Dual-virion vaccine antigens; decades-long immune durability

Protective immunity must target IMV and EEV antigens; both first- and third-generation vaccines elicit antibodies, with strongest responses to EEV antigens B5 and A33, retained 40–80 years after Dryvax PMID: 40311645. T-cell responses are more sustained than waning antibody PMID: 41012133; historical vaccination confers ~70% residual cross-protection against mpox PMID: 39176988.

Mechanistic Model / Interpretation

INFECTION → ENTRY → DISSEMINATION → IMMUNE EVASION → TISSUE INJURY → OUTCOME

Respiratory       GAG-dependent        Monocyte-          SPICE blocks        Epithelial        Ordinary
droplet/aerosol → attachment (4    →   associated     →   complement @   →    replication   →   smallpox
on oropharynx     MV proteins) +       viremia to         C3 convertase;      → rash;           (CFR ~10-30%)
  11-12 protein        lymph nodes,        chemokine/          enanthem
  entry-fusion         spleen, skin,       cytokine binders                        OR
  complex              mucosa, liver       blunt innate                         Flat/hemorrhagic
                                           immunity            Cytokine storm    (CFR >95%)
                                                               + coagulopathy →
                                                               multi-organ
                                                               failure

The coherent narrative: VARV is an exquisitely human-adapted orthopoxvirus whose large immune-evasion arsenal (exemplified by human-selective SPICE) permits efficient dissemination via host monocytes. Disease severity is a branch determined by the balance between viral replication/immune-evasion and the host adaptive/cytokine response — tipping toward lethal coagulopathic failure in flat/hemorrhagic forms. The same dual-virion biology that complicates vaccine design (needing both IMV and EEV antigens) also explains why vaccinia-based immunity is broadly cross-protective and remarkably durable, which made ring vaccination of a reservoir-free, strictly human pathogen sufficient for eradication.

Evidence Base (selected)

PMID Role
12941397 VARV genome content & immune-evasion gene complement
42576544 Eradication date, biodefense, ACAM2000 safety
42135325 Somalia 1976–77 outbreak data; eradication 1980
15477589 Variola macaque model — viremia & dissemination
25653439 Aerosol mpox macaque — temporal pathogenesis & cytokines
28749451 Two-clade VARV phylogeny; historical specimens
34253028 Orthopoxvirus antidefense-gene evolution
22754644 Poxvirus entry machinery
38321165 D8 drives membrane curvature for fusion
18768877 SPICE GAG anchoring & C3 convertase inhibition
19667083 SPICE functional sites; inhibitory mAb
28724763 SPICE human-pathway selectivity vs VCP
41740032 Tecovirimat Animal-Rule approval; mpox trial null result
36688308 Brincidofovir as second oral smallpox antiviral
21431786 Vaccination strategy, adverse events, post-exposure window
16933957 Strain-dependent vaccine adverse-event rates
40311645 EEV antigen dominance; 40–80 yr durability
41012133 Durable T-cell vs waning antibody
39176988 ~70% residual cross-protection vs mpox
34851148 4pox DNA vaccine (L1/A27/B5/A33)
41941064 Dual-virion rational/mRNA vaccine design

Limitations and Knowledge Gaps

  1. No human efficacy data for antivirals or modern vaccines against actual smallpox — all approvals rest on surrogate animal models (Animal Rule). The negative tecovirimat mpox trial PMID: 41740032 raises genuine uncertainty about real-world efficacy against human orthopoxvirus disease.
  2. Surrogate-model fidelity: Variola macaque models require non-physiologic high IV doses; mpox/rabbitpox/mousepox are related but distinct viruses, so pathogenesis inferences carry extrapolation risk.
  3. Host-susceptibility genetics are uncharacterized — eradication preceded modern GWAS/omics, so no human susceptibility or modifier loci exist.
  4. Correlates of protection remain undefined — the relative contribution of antibody vs T-cell immunity to durable protection is not fully resolved PMID: 41012133.
  5. Molecular pathophysiology of the hemorrhagic form (cytokine-storm/coagulopathy triggers) is inferred from animal models rather than demonstrated in humans.
  6. Antiviral resistance (tecovirimat VP37 mutations) threatens monotherapy efficacy, and combination-therapy evidence is immature PMID: 41038284.

Proposed Follow-up Experiments / Actions

  1. Define immune correlates of protection by longitudinally measuring IMV- vs EEV-directed antibody and T-cell responses after MVA-BN and correlating with protection in NHP challenge, to establish a surrogate endpoint usable for regulatory decisions.
  2. Combination antiviral studies (tecovirimat + brincidofovir/cidofovir) in NHP variola and rabbitpox models to pre-empt resistance and strengthen the countermeasure stockpile.
  3. Structural/functional targeting of SPICE — advance the inhibitory monoclonal antibody PMID: 19667083 as an adjunct therapeutic that restores complement-mediated clearance.
  4. Next-generation multivalent mRNA vaccines co-targeting conserved IMV (A27/L1) and EEV (B5/A33) antigens, evaluated for durability, imprinting effects, and cross-clade/pan-orthopox coverage PMID: 41941064.
  5. Preparedness surveillance leveraging digitized historical outbreak data PMID: 42135325 and rapid PCR/sequencing diagnostics to distinguish re-emergent VARV (bioterror scenario) from circulating mpox and novel orthopoxviruses PMID: 28329402.
  6. Characterize residual population immunity in pre-1980 vaccinated cohorts to inform ring-vaccination feasibility should VARV re-emerge.

Report compiled from 7 confirmed findings and 51 reviewed papers over 5 investigation iterations. Evidence types span human clinical/historical, nonhuman-primate and rodent models, in vitro mechanistic, and computational/phylogenetic sources.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.4.0.

Outcome Count
References checked 32
Resolved 32
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 3
Quoted claims found in source 3
Quoted claims not found in source 0
References weighed for topical relevance 32
On topic 23
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 30
Resolved 30
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0
Terms whose name was checked 20
Terms named correctly 9
Terms named as a different term 4
Terms whose name is worth a second look 7

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0004651 (4 mentions) - the report calls it "if available", "MONDO"; MONDO calls it smallpox
  • HP:0000987 (2 mentions) - the report calls it "Permanent, disfiguring; healed survivors"; HP calls it Atypical scarring of skin
  • NCIT:C171621 (1 mention) - the report calls it "Tecovirimat"; NCIT calls it Impact of Events Scale
  • NCIT:C97660 (1 mention) - the report calls it "Brincidofovir"; NCIT calls it Abemaciclib

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • HP:0000164 (1 mention) - the report calls it "Oral mucosa abnormality"; HP calls it Abnormality of the dentition, and lists "Dental abnormality" among its other names
  • HP:0200039 (1 mention) - the report calls it "Papule"; HP calls it Pustule, and lists "Pimple" among its other names
  • HP:0001974 (1 mention) - the report calls it "Leukocytosis"; HP calls it Increased total leukocyte count, and lists "Leukocytosis" among its other names
  • GO:0046718 (1 mention) - the report calls it "viral entry into host cell"; GO calls it symbiont entry into host cell, and lists "viral entry into host cell" among its other names
  • UBERON:0002097 (1 mention) - the report calls it "Primary: Skin"; UBERON calls it skin of body**, and lists "entire skin" among its other names
  • UBERON:0000029 (1 mention) - the report calls it "Lymphoreticular system: lymph nodes"; UBERON calls it lymph node**
  • UBERON:0000160 (1 mention) - the report calls it "Secondary: Gastrointestinal tract"; UBERON calls it intestine**, and lists "intestinal tract" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • MONDO:0004651 - called "if available", "MONDO"